How have the shares performed?
Virios Therapeutics LLC (VIRI) saw an uptrend of 9.25% in the recent trading with $6.14 being its most recent. The current price level -63.26% lower than the highest price of $16.71 marked by the stock while trading over the past 52-weeks, whereas it is 33.48% higher than the lowest price of $4.60 the company dropped to over past 52-weeks. The latest news story on VIRI appeared in Benzinga under the title “Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial” on Jun-09-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -11.63% below one month high and is +31.93% above of the lowest during that time. Looking into the simple moving average, Virios Therapeutics LLC (VIRI)’s stock stands at a SMA-50 of $5.48 while that of 5-day is reading $5.65.
Virios Therapeutics LLC Earnings – What Happened With VIRI
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
VIRI – Virios Therapeutics LLC Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 8.33 million. VIRI does have institutional investors; and they hold 10.30% of the stock.
Virios Therapeutics LLC – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 4 new insider purchases involving 32,732 shares. On the other hand, VIRI declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Mar 30, 2021, Masters Capital Management, LLC was the top most holder in Virios Therapeutics LLC (NASDAQ:VIRI) with an ownership of 0.6 million shares of the company or 7.20% of the stake worth $3.44 million. The filing also reveals Two Sigma Investments, LP as the second largest holder in the company with a control over 1.29% of the outstanding shares. Its stake is worth $0.62 million for having 0.11 million shares in hand.
PVG Asset Management Corp also came holding a key position in the company during the recent quarter and it now holds 0.66% of the outstanding shares. With this there are now 13 institutions which have possession in VIRI’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Virios Therapeutics LLC was 20.55 while posting a debt to equity ratio of 0.00.
Virios Therapeutics LLC’s return on equity, or ROE, is -113.30%, compared to the industry average of -40.21% for Healthcare – Biotechnology. Although this indicates that VIRI fails to use its equity well, the metric will vary significantly depending on the industry.